Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

(1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mladen Japjec, Katarina Horvat Pavlov, Andreja Petrovic, Mario Staresinic, Bozidar Sebecic, Matko Buljan, Hrvoje Vranes, Ana Giljanovic, Domagoj Drmic, Miroslav Japjec, Andreja Prtoric, Eva Lovric, Lovorka Batelja Vuletic, Ivan Dobric, Alenka Boban Blagaic, Anita Skrtic, Sven Seiwerth, Sikiric Predrag
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	nitric oxide oxidative stress BPC 157 therapy myotendinous junctions leg contracture walking recovery index Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/66217dcf180941f0954546663f543da1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66217dcf180941f0954546663f543da1
record_format	dspace
spelling	oai:doaj.org-article:66217dcf180941f0954546663f543da12021-11-25T16:48:52ZStable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats10.3390/biomedicines91115472227-9059https://doaj.org/article/66217dcf180941f0954546663f543da12021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1547https://doaj.org/toc/2227-9059(1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, <i>eNOS</i>, and <i>COX-2</i> mRNA levels and oxidative stress and NO-levels in the myotendinous junctions. BPC 157 (10 µg/kg, 10 ng/kg) regimen was given (i) intraperitoneally, first application immediately after surgery, last 24 h before sacrifice; (ii) per-orally, in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat/day), till the sacrifice at 7, 14, 28 and 42 postoperative days. (3) Results: These BPC 157 regimens document prominent therapy effects (macro/microscopic, biomechanical, functional much like <i>eNOS</i> and <i>COX-2</i> mRNA levels and counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation. Especially, in rats with the disabled myotendinous junction, along with full functional recovery, BPC 157 counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal. Accordingly, unlike the perilous course in controls, those rats, when receiving BPC 157 therapy, exhibit a smaller defect, and finally defects completely disappear. Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days. (4) Conclusions: BPC 157 restores myotendinous junction in accordance with the healing of the transected muscle, tendon, and ligament.Mladen JapjecKatarina Horvat PavlovAndreja PetrovicMario StaresinicBozidar SebecicMatko BuljanHrvoje VranesAna GiljanovicDomagoj DrmicMiroslav JapjecAndreja PrtoricEva LovricLovorka Batelja VuleticIvan DobricAlenka Boban BlagaicAnita SkrticSven SeiwerthSikiric PredragMDPI AGarticlenitric oxideoxidative stressBPC 157 therapymyotendinous junctionsleg contracturewalking recovery indexBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1547, p 1547 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nitric oxide oxidative stress BPC 157 therapy myotendinous junctions leg contracture walking recovery index Biology (General) QH301-705.5
spellingShingle	nitric oxide oxidative stress BPC 157 therapy myotendinous junctions leg contracture walking recovery index Biology (General) QH301-705.5 Mladen Japjec Katarina Horvat Pavlov Andreja Petrovic Mario Staresinic Bozidar Sebecic Matko Buljan Hrvoje Vranes Ana Giljanovic Domagoj Drmic Miroslav Japjec Andreja Prtoric Eva Lovric Lovorka Batelja Vuletic Ivan Dobric Alenka Boban Blagaic Anita Skrtic Sven Seiwerth Sikiric Predrag Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
description	(1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, <i>eNOS</i>, and <i>COX-2</i> mRNA levels and oxidative stress and NO-levels in the myotendinous junctions. BPC 157 (10 µg/kg, 10 ng/kg) regimen was given (i) intraperitoneally, first application immediately after surgery, last 24 h before sacrifice; (ii) per-orally, in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat/day), till the sacrifice at 7, 14, 28 and 42 postoperative days. (3) Results: These BPC 157 regimens document prominent therapy effects (macro/microscopic, biomechanical, functional much like <i>eNOS</i> and <i>COX-2</i> mRNA levels and counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation. Especially, in rats with the disabled myotendinous junction, along with full functional recovery, BPC 157 counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal. Accordingly, unlike the perilous course in controls, those rats, when receiving BPC 157 therapy, exhibit a smaller defect, and finally defects completely disappear. Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days. (4) Conclusions: BPC 157 restores myotendinous junction in accordance with the healing of the transected muscle, tendon, and ligament.
format	article
author	Mladen Japjec Katarina Horvat Pavlov Andreja Petrovic Mario Staresinic Bozidar Sebecic Matko Buljan Hrvoje Vranes Ana Giljanovic Domagoj Drmic Miroslav Japjec Andreja Prtoric Eva Lovric Lovorka Batelja Vuletic Ivan Dobric Alenka Boban Blagaic Anita Skrtic Sven Seiwerth Sikiric Predrag
author_facet	Mladen Japjec Katarina Horvat Pavlov Andreja Petrovic Mario Staresinic Bozidar Sebecic Matko Buljan Hrvoje Vranes Ana Giljanovic Domagoj Drmic Miroslav Japjec Andreja Prtoric Eva Lovric Lovorka Batelja Vuletic Ivan Dobric Alenka Boban Blagaic Anita Skrtic Sven Seiwerth Sikiric Predrag
author_sort	Mladen Japjec
title	Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
title_short	Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
title_full	Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
title_fullStr	Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
title_full_unstemmed	Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
title_sort	stable gastric pentadecapeptide bpc 157 as a therapy for the disable myotendinous junctions in rats
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/66217dcf180941f0954546663f543da1
work_keys_str_mv	AT mladenjapjec stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT katarinahorvatpavlov stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT andrejapetrovic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT mariostaresinic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT bozidarsebecic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT matkobuljan stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT hrvojevranes stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT anagiljanovic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT domagojdrmic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT miroslavjapjec stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT andrejaprtoric stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT evalovric stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT lovorkabateljavuletic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT ivandobric stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT alenkabobanblagaic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT anitaskrtic stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT svenseiwerth stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats AT sikiricpredrag stablegastricpentadecapeptidebpc157asatherapyforthedisablemyotendinousjunctionsinrats
_version_	1718412958852186112

Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

Ejemplares similares